When it comes to venture capital invested in the first quarter of 2019, Houston raked in less than 10 percent of what Austin reported, but the state as a whole has seen an increase, according to Crunchbase. Getty Images

While the state marked significant growth in first quarter venture capital investments year over year, Houston fell far behind its Texas sister cities. Houston startups received just 10 percent of what Austin startups reported, and Houston lost its lead it's had on Dallas for two quarters, according to Crunchbase data.

Texas had a reported $790.4 million in Q1, per Crunchbase, which is up from Q4 2018's $530.6 million as well as being up year over year from $587.2 million in Q1 of 2018. The number of deals for the state was cut almost by half — 64 Q1 2019 deals compared to 118 in Q1 of 2018 — "indicating larger investment sizes as the state's startup market continues to mature," according to Crunchbase's Mary Ann Azevedo.

Meanwhile in Houston, the city's startups received $44.7 million of that reported investment last quarter, which is down from the $121.4 million reported in Q4 2018. Austin raked in $493.8 million — more than 10 times that of Houston — and Dallas reported $245.4 million, which more than doubles what they reported for Q4 of 2018.

Houston lost its lead it had on Dallas for the past two quarters. In Q4 of 2018, Houston outdid Dallas with $121 million in venture capital investment, according to Crunchbase. Before that, Houston crushed Dallas in the third quarter too with $138.8 million compared to Dallas' $38.1 million. That quarter was when Houston came close to Austin's VC funding.

The largest deal in Houston was for biotech startup, Solugen, which closed its $13 million Series A in March, Cruncbase reported, and Y Combinator contributed to the round.

The Crunchbase report mentioned a few huge deals that tipped the scale this time around for Austin and Dallas. Dallas-based Peloton Therapeutics closed a $150 million Series E round in February. In Austin, Disco — a company founded in Houston but relocated to Austin — closed a $83 million Series E round, and Austin's Billd drew in $60 million in a Series A.

Houston's cut shrinks

Houston's piece of the Texas VC pie continues to shrink. In Q3 2018, the city had a third of the funds and, in Q4, had over 20 percent.Via Crunchbase News

Dallas is back at No. 2

Dallas came back with a vengeance after being outdone by Houston for the past two quarters.Via Crunchbase News

LiveOak Venture Partners, an Austin-based firm, is the first recipient of Houston Exponential's fund of funds. Courtesy of LiveOak

Houston venture fund of funds doles out $5 million in Austin firm in its first investment

money moves

After closing its initial round of funding last year, Houston Exponential's fund of funds, called the HX Venture Fund, has closed its first investment on March 29. Austin-based LiveOak Venture Partners received a $5 million investment from the fund.

The HX Venture Fund raised $30 million after launching in October of last year. The fund's goal is to invest in out-of-Houston venture funds in the hopes that they reinvest that money into Houston startups.

"We invested in LiveOak Venture II because of the firm's compelling investment track record, expertise and vigor of the general partners, their extensive network of relationships with proven entrepreneurs, and their focus on capital efficient early stage technology companies in Texas," says Guillermo Borda, managing partner at HX Venture Fund, in a release. "LiveOak's team is committed to making a significant impact in the Houston startup ecosystem."

The HX investment is a part of LiveOak's Fund II, which was oversubscribed and closed at $105 million, the company announced today. According to a release from LiveOak, Fund II is a continuation to the firm's dedication to Texas entrepreneurship. The fund will focus on funding within the state's four largest tech hubs — Austin, Houston, Dallas and San Antonio — and have initial investments ranging from $2 million to $4 million, the release states.

The firm's portfolio focuses on seed and series A funding, and most of its investments are Austin-based, with the exception of three Dallas companies. LiveOak invested in Houston-founded CS Disco, an AI-enabled tool for legal business, but the company has since moved to Austin, according to a public relations representative. LiveOak also invested in San Antonio-founded Infocyte, but the company also relocated to Austin.

Houston has been a strategic market for LiveOak, says managing partner, Krishna Srinivasan, in the release, citing the city's recent entrepreneurial activity.

"We are excited to partner with HX Venture Fund and its strategic investment partners, comprising multiple leading Houston based corporations, to catalyze and grow this activity," says Srinivasan, in the release. "Given LiveOak's investment strategy of being the leading source of capital for entrepreneurs across Texas, we view this investment as highly synergistic with our efforts to enable world-class, category dominating companies coming out of Houston."

HX modeled its fund after the Renaissance Venture Capital Fund in Michigan, from which 10 outside venture capital firms benefitted. Renaissance Fund reported positive results from the fund of funds and Chris Rizik, CEO and fund manager of Renaissance, serves as a member of the investment committee.

Texas venture capital deals had its first spike in volume last year since 2013. Getty Images

Report finds Houston venture capital firm has made the most Texas deals since 2010

At the top

When it comes to tracking venture capital deals coming out of Texas since 2010, a Houston fund tops the list — but just barely. Houston Angel Network edged out Austin-based Central Texas Angel Network by one deal.

The report by PitchBook counted deals from 2010 up to March 4 that were made with Texas companies. Ten VC funds were listed and, aside from HAN, Mercury Fund was the only other Houston VC. The other eight funds are located central Texas — with the exception of Right Side Capital Management, which has invested in 45 Texas companies since 2010.

"Texas is currently in a transition powered by high-tech investments that lie in contrast to the slow-paced cattle ranches spread throughout the rural areas of the country's 28th state," the report states. "Partly as a result of the relatively new tech scene, Texas was home to three of the 10 fastest-growing cities in the United States in 2018, according to Forbes."

According to the data, VC funding had been on a downward trend since 2013, when the state raked in $2.83 billion in 536 deals. However, 2018 marked a turn for the state with $3.11 billion in 461 deals — a smaller deal count compared to 2013.

Despite this VC deal growth, compared to the rest of the country, Texas ranks fourth when it comes to VC investment market share. California holds over 52 percent of the market, New York has over 10 percent, and Massachusetts has almost 10 percent itself, per PitchBook data. Meanwhile, Texas reportedly holds only 3.43 percent of the market.

PitchBook also identified the top 10 VC deals investing in Texas companies closed since the beginning of 2018 — none of which were into Houston companies. The list's top three had nine-figure investments — Austin-based Bungalo with a $250 million Series A, Dallas-based Peloton Therapeutics with a $150 million Series E, and Richardson, Texas-based Hedera Hashgraph with a $101 million Seed round.

Graph via PitchBook

Texas startups should be getting funded with Texas money, and here's why. Getty Images

Why it's important for Texas startups to get funding within the Lone Star State

Stay local

When you set out to disrupt a long-standing industry, one of the most important aspects is figuring out where you are going to get the money. Odds are, you are going to be OK with breaking the mold on other traditional practices such as forgoing the venture capitalist firms for smaller companies who share your innovative vision and want to invest in it.

That philosophy works well in Texas seeing as the big venture capitalists tend to stay on the East and West Coasts.

There are dozens of things to think about when starting a company. Funding can be the most important, and there are many ways to approach raising funding for your startup. Here are a few things to consider.

Think local

They say everything is bigger in Texas, and one thing is for certain, the Texas economy is thriving and historically very stable. Five of the top 10 fastest-growing cities in the U.S. are in Texas, and a recent Federal Reserve Bank of Dallas report found that Texas is the top state for corporate relocations due to our business-friendly climate.

Benefits of the Texas economy

Business owners and investors alike are noticing the rapid job growth, low tax rates, minimal regulation, successful economic development, and the fact that Texas is the largest exporting state in the nation.

It's important to explore and evaluate all of your options because there are investors everywhere – big and small. I explored fundraising in other states and had I gone that route, it most likely would have led to a successful fundraising campaign. However, it would have looked a lot different. I learned during the first round of fundraising that as much as the angel investment matters, the first meaningful investment might matter even more.

Explore family office investors — it's personal

Traditionally, companies looking for investors seek out the venture capitalist firms with deep pockets. You can joke that Texas is a venture capitalist desert. Compared to the "coasts," there are not many venture capitalist firms here.

I realized that what Texas does have plenty of, is family office investors. And I quickly learned that it was this type of organization that I truly desired. Why? Because local family offices are more likely to share your "homegrown" startup vision. They have true vested interest and it is really personal for them.

Also, the younger generations of these family businesses often lead the way in extending beyond oil wells, fracking, shopping centers and agriculture in seeking to invest in technology startups.

Expert tip: We used our personal connections to target regional investors such as Court Wescott; the founder of 1-800-Flowers; retired Hollywood Casinos CEO Jack Pratt; The Murchison Family; and residential real estate developer Phillip Huffines. We were able to successfully reach around $12 million in the Series A round of fundraising.

When we were ready for the next round of fundraising, we had everything we needed right here in Texas.

Great ideas get funded

Venture capitalists who put a lot of money into a lot of companies also delegate to those companies a lifespan, or a timeline for getting their money back.

Since the family offices believed in our concept and understood what we were doing, we were seen as more of a long-term investment and therefore given a longer time horizon than we would if we had gone the more traditional route of fundraising.

Investors like to watch their investments grow and typically they have more money for second and third rounds of funding when you can prove your success in the first few years.

The bottom line: Investing in Texas companies is a beneficial strategy due to the Lone Star State's booming economy and investing in companies that you believe in makes for a more meaningful relationship, which helps everyone involved succeed.

------

Alex Doubet is the CEO and founder of Door Inc., a Texas-based, tech-infused real estate platform.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”